Market News
Recent Developments:
New product launches:
- In August 2022, Respiri, a mobile app runs a wheeze detection algorithm to identify wheeze and display a wheeze rate launched its Wheezo asthma monitoring device in the U.S. market. The device helps patients to monitor symptoms and medication usage.
- In June 2021, Cipla, a healthcare company; received U.S. FDA approval for its Arformoterol Tartrate Inhalation solution, used for treating COPD. The drug helped to improve access to treatment.
- In December 2021, NuvoAir, a virtual-first specialty care provider that empowers and engages people living with complex heart and lung conditions; released an add-on sensor for asthma and chronic obstructive pulmonary disease (COPD) inhalers as a part of its chronic care ecosystem. The NuvoAir Aos sensor provides additional data to the service platform by enabling NuvoAir Care Coordinators and healthcare providers to assess inhaler technique, monitor inhaler use and evaluate treatment effectiveness.
Acquisition and partnerships:
- In September 2022, Respiri signed a distribution agreement with pharmacy chain Medisummary for launching Wheezo in over 125 pharmacies across Australia.
- In June 2022, PARI partnered with NuvoAir to integrate connected inhaler devices for remote patient monitoring and improved compliance.
U.S.: 
U.K. : 
India : 
